05/06/2025
Good to have this now shown with a rigorous study, as clinical practice has been supporting this for a while now.
Indian researchers have just published a randomized, double-blind, placebo-controlled trial of individualized homeopathy for patients testing positive for COVID-19.
Two hundred and sixty-nine participants who tested positive for COVID-19 infection (N Gene, ORF 1-ab-Gene, and the S Gene of the SARS COV-2 virus) were randomized into two parallel groups. A total of 133 participants (49 %) were randomized to the homeopathic group. The remaining 136 (51 %) patients in the control group received a placebo intervention in addition to standard care of modern medicine.
The results:
"Of the 269 participants, 133 (49 %) were in the homoeopathic group and 136 (51 %) were in the control group. There were no significant differences in the demographic characteristics, comorbidities, or allopathic treatment administered within the groups at baseline. The median scores for shortness of breath, cough, weakness, and fatigue significantly reduced on days five and ten. There were no significant differences in the median values of inflammatory markers. The ICU requirement (p = 0.01), ventilator requirement (p = 0.01), and mortality (p = 0.003) were significantly lower in the homoeopathic group."
Conclusion
"Homoeopathy as an adjuvant to standard care in the management of COVID-19 resulted in lowering of clinical symptoms, and a significantly lower ICU requirement, requirement of ventilation, and mortality rate compared to standard care alone."
Source: Govindarajan Sankaran, Anil Khurana, Leena Shah, Kishor Khillare, Debadatta Nayak, Navin Pawaskar. A randomized placebo-controlled clinical trial using Homoeopathy as an adjuvant to standard care in the management of COVID-19,
Advances in Integrative Medicine, 2025.